You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 157 No. 13, 14 JULY 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL OBSERVATION
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Fulminant Pneumocystis carinii Pneumonia in 4 Patients With Dermatomyositis

Hervé Bachelez, MD; Bruno Schremmer, MD; Jacques Cadranel, MD; Frédéric Mouly, MD; Claudine Sarfati, MD; Felix Agbalika, MD; Benoit Schlemmer, MD; Charles-Marie Mayaud, MD; Louis Dubertret, MD

Arch Intern Med. 1997;157(13):1501-1503.


Abstract

Between 1989 and 1996, 4 cases of Pneumocystis carinii pneumonia (PCP) were observed in patients seronegative for the human immunodeficiency virus who were receiving corticosteroid therapy for dermatomyositis in our institution. These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone. In all 4 patients lymphopenia was observed before the initiation of corticosteroid treatment and low CD4 and CD8 cell counts were evident at the time of PCP. These observations support the view of an increase in both the severity and incidence of PCP in patients without human immunodeficiency virus infection and question the need for a primary prophylaxis in patients with connective tissue diseases receiving high-dose corticosteroid therapy.

Arch Intern Med. 1997;157:1501-1503



Author Affiliations

From the Institut de Recherche sur la Peau and the Services de Dermatologie 1 (Drs Bachelez and Dubertret), Réanimation Médicale (Drs Schremmer and Schlemmer), and Dermatologie 2 (Dr Mouly), the Laboratoire de Parasitologie (Dr Sarfati), and the Laboratoire de Virologie (Dr Agbalika), Hôpital Saint-Louis, and the Service de Pneumologie, Hôpital Tenon (Drs Cadranel and Mayaud), Paris, France.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Incidence, Risk Factors, and Severity of Herpesvirus Infections in a Cohort of 121 Patients With Primary Dermatomyositis and Dermatomyositis Associated With a Malignant Neoplasm
Fardet et al.
Arch Dermatol 2009;145:889-893.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.